Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis

OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). This study was undertaken to evaluate the risk of major adverse cardiovascular events (MACE) in patients with RA receiving tofacitinib. METHODS: Data were pooled from patients with moderately to severely...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Arthritis Rheumatol
Autors principals: Charles‐Schoeman, Christina, DeMasi, Ryan, Valdez, Hernan, Soma, Koshika, Hwang, Lie‐Ju, Boy, Mary G., Biswas, Pinaki, McInnes, Iain B.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2019
Matèries:
Rheumatoid Arthritis
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6754249/
https://ncbi.nlm.nih.gov/pubmed/31385441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40911
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars